Protective antigen as a correlative marker for anthrax in animal models

被引:65
作者
Kobiler, David
Weiss, Shay
Levy, Haim
Fisher, Morly
Mechaly, Adva
Pass, Avi
Altboum, Zeev
机构
[1] Israel Inst Biol Res, Dept Infect Dis, IL-74100 Ness Ziona, Israel
[2] Israel Inst Biol Res, Dept Biotechnol, IL-74100 Ness Ziona, Israel
关键词
D O I
10.1128/IAI.00792-06
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The most aggressive form of anthrax results from inhalation of airborne spores of Bacillus anthracis and usually progresses unnoticed in the early stages because of unspecific symptoms. The only reliable marker of anthrax is development of bacteremia, which increases with disease progress. Rapid diagnosis of anthrax is imperative for efficient treatment and cure. Herein we demonstrate that the presence and level of a bacterial antigen, the protective antigen (PA), a component of B. anthracis toxins, in host sera can serve as a reliable marker of infection. This was tested in two animal models of inhalation anthrax, rabbits and guinea pigs infected by intranasal instillation of Vollum spores. In both models, we demonstrated qualitative and quantitative correlations between levels of bacteremia and PA concentrations in the sera of sick animals. The average time to death in infected animals was about 16 h after the appearance of bacteremia, leaving a small therapeutic window. As the time required for immunodetection of PA can be very short, the use of this marker will be beneficial for faster diagnosis and treatment of inhalation anthrax.
引用
收藏
页码:5871 / 5876
页数:6
相关论文
共 31 条
[1]  
ALBRINK WS, 1959, AM J PATHOL, V35, P1055
[2]   Postexposure prophylaxis against anthrax: Evaluation of various treatment regimens in intranasally infected guinea pigs [J].
Altboum, Z ;
Gozes, Y ;
Barnea, A ;
Pass, A ;
White, M ;
Kobiler, D .
INFECTION AND IMMUNITY, 2002, 70 (11) :6231-6241
[3]   Management of anthrax [J].
Bartlett, JG ;
Inglesby, TV ;
Borio, L .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (07) :851-858
[4]   Gram-positive rod surveillance for early anthrax detection [J].
Begier, EM ;
Barrett, NL ;
Mshar, PA ;
Johnson, DG ;
Hadler, JL .
EMERGING INFECTIOUS DISEASES, 2005, 11 (09) :1483-1486
[5]  
BERDJIS CC, 1962, BRIT J EXP PATHOL, V43, P515
[6]  
Brachman P S, 1980, Ann N Y Acad Sci, V353, P83, DOI 10.1111/j.1749-6632.1980.tb18910.x
[7]   INDUSTRIAL INHALATION ANTHRAX [J].
BRACHMAN, PS ;
KAUFMANN, AF ;
DALLDORF, FG .
BACTERIOLOGICAL REVIEWS, 1966, 30 (03) :646-&
[8]   The prophylaxis and treatment of anthrax [J].
Brook, I .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (05) :320-325
[9]  
Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P973
[10]   Anthrax toxin [J].
Collier, RJ ;
Young, JAT .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2003, 19 :45-70